{
  "model": "gpt-oss-120b",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 3,
  "workspacePath": "workspaces/gpt-oss-120b-tumor-vaccine-ici-run-3",
  "success": false,
  "schemaPass": false,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 127590,
  "agentCostUsd": 0,
  "graderCostUsd": 0.016719499999999998,
  "totalCostUsd": 0.016719499999999998,
  "agentUsage": {
    "promptTokens": 54302,
    "cachedTokens": 16422,
    "responseTokens": 6649,
    "thinkingTokens": 0,
    "totalTokens": 60951
  },
  "graderUsage": {
    "promptTokens": 3858,
    "cachedTokens": 0,
    "responseTokens": 524,
    "thinkingTokens": 188,
    "totalTokens": 4570
  },
  "totalUsage": {
    "promptTokens": 58160,
    "cachedTokens": 16422,
    "responseTokens": 7173,
    "thinkingTokens": 188,
    "totalTokens": 65521
  },
  "modelVersions": [
    "accounts/fireworks/models/gpt-oss-120b"
  ],
  "agentFinalText": "✅ Completed:\n- output/study_overview.json\n- output/quantitative_findings.json\n- output/claim_audit.json\n- output/public_summary.json",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to immune checkpoint blockade therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 mice\",\n      \"description\": \"78 tumor‑bearing mice receiving combination of intratumoral mRNA vaccine and anti‑PD‑L1 therapy across repeat experiments.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 mice\",\n      \"description\": \"84 tumor‑bearing mice receiving vaccine‑only, ICI‑only, or vehicle control groups.\"\n    },\n    {\n      \"id\": \"human-retrospective\",\n      \"label\": \"Human retrospective cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"130 metastatic cancer patients treated with immune checkpoint inhibitors, assessed by prior SARS‑CoV‑2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"43 patients in the retrospective cohort who had received a SARS‑CoV‑2 mRNA vaccine before ICI therapy.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"87 patients in the retrospective cohort without prior mRNA vaccination.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"Retrospective human analysis is non‑randomized, risking confounding.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Mouse model findings may not translate directly to all human tumors.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": false,
      "groundingValid": false,
      "errors": [
        "controls_or_null_results.0.evidence_line_ref: Invalid input: expected string, received array",
        "controls_or_null_results.1.evidence_line_ref: Invalid input: expected string, received array"
      ],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I‑presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p‑value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD‑L1 expression fold‑change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T‑cell density fold‑change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine‑only treatment did not produce durable tumor control in non‑immunogenic models.\",\n      \"evidence_line_ref\": [\"L36\"]\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti‑IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": [\"L39\"]\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": false,
      "errors": [
        "Quote in C03 was not found verbatim in report: \"Retrospective human survival comparison p‑value | p=0.01 | N/A\"",
        "Quote in C04 was not found verbatim in report: \"Blocking type I interferon signaling with anti‑IFNAR1 eliminated the observed sensitization benefit.\"",
        "Quote in C04 was not found verbatim in report: \"Interferon‑associated antigen processing and presentation pathways increase.\""
      ],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination combined with anti‑PD‑L1 therapy improves tumor control in mouse models.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"Mouse model results may not directly translate to human clinical outcomes.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination markedly raises the tumor type I interferon response score.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"The interferon score is a normalized metric and its clinical relevance is not fully established.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Patients previously vaccinated with SARS‑CoV‑2 mRNA vaccines show improved survival when treated with immune checkpoint inhibitors.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p‑value | p=0.01 | N/A\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non‑randomized, so confounding factors may influence the observed survival benefit.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Blocking type I interferon signaling with anti‑IFNAR1 eliminates the sensitization effect of mRNA vaccination.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti‑IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Interferon‑associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"The blockade experiments were performed in preclinical models; human relevance requires further validation.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"Intratumoral mRNA vaccines boost tumor antigen presentation and improve checkpoint inhibitor outcomes in mice and humans\",\n  \"plain_language_summary\": \"The study shows that delivering an mRNA vaccine directly into tumours triggers a strong local immune response, increasing the variety of tumour proteins displayed to the immune system and raising type‑I interferon activity. In mouse models, this makes anti‑PD‑L1 therapy more effective, cutting tumour growth. In a retrospective analysis of 130 metastatic cancer patients, those who had received a SARS‑CoV‑2 mRNA vaccine before starting checkpoint inhibitor therapy lived longer, with a statistically significant survival advantage (p=0.01). However, the human data are observational, and the timing of vaccination varied, so the results need confirmation in prospective trials.\",\n  \"what_is_new\": [\n    \"mRNA vaccination directly in tumours expands the immunopeptidome, increasing antigen visibility for T cells.\",\n    \"Combination of intratumoral mRNA vaccine with anti‑PD‑L1 markedly improves tumour control in mouse models.\",\n    \"Retrospective human data suggest prior SARS‑CoV‑2 mRNA vaccination is associated with better survival under checkpoint blockade.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human cohort analysis is retrospective and not randomised, so confounding factors may drive the observed survival benefit.\",\n    \"Vaccination timing relative to checkpoint therapy varied among patients, potentially influencing outcomes.\",\n    \"Findings from mouse models may not fully translate to the diversity of human cancers.\"\n  ],\n  \"glossary\": [\n    {\"term\": \"Immunopeptidome\", \"definition\": \"The complete set of peptide fragments presented by major histocompatibility complex (MHC) molecules on the surface of a cell, which can be recognised by T cells.\"},\n    {\"term\": \"Type I interferon\", \"definition\": \"A group of cytokines that are rapidly produced in response to viral infection and help activate immune cells, enhancing antigen presentation and antiviral defenses.\"},\n    {\"term\": \"Anti‑PD‑L1 therapy\", \"definition\": \"A checkpoint inhibitor that blocks the interaction between PD‑L1 on tumour cells and PD‑1 on T cells, releasing the brake on the immune response against cancer.\"},\n    {\"term\": \"Retrospective cohort\", \"definition\": \"A study design that looks back at existing data from a group of subjects to examine outcomes and associations after the events have occurred.\"}\n  ],\n  \"open_questions\": [\n    \"Will prospective randomised trials confirm that intratumoral mRNA vaccination improves checkpoint inhibitor efficacy in humans?\",\n    \"What is the optimal timing and dosing schedule for combining mRNA vaccines with checkpoint blockade?\",\n    \"How broadly applicable are these findings across different tumour types and patient populations?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 25,
    "failedCalls": 1,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory",
        "error": "Invalid tool arguments for list_directory: dir_path: Too small: expected string to have >=1 characters"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 12,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 13,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-16T12:59:05.331Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": ".",
        "timestamp": "2026-02-16T12:59:08.953Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-16T12:59:10.571Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-16T12:59:11.906Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-16T12:59:13.214Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-16T12:59:14.871Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-16T12:59:16.782Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-16T12:59:17.726Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-16T12:59:53.358Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-16T13:00:18.597Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-16T13:00:39.799Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-16T13:00:51.961Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "value": {
      "verdict": "fail",
      "scores": {
        "faithfulness": 3,
        "coverage": 5,
        "usefulness": 4
      },
      "critical_issues": [
        "output/quantitative_findings.json has schema/grounding failures: controls_or_null_results.*.evidence_line_ref is an array (e.g., [\"L36\"]) but validation expects a string. This makes the output less reliable for downstream automated review and violates the requirement that line references be valid/useful.",
        "output/claim_audit.json has grounding failures because multiple quoted strings are not verbatim in the report despite being presented as direct quotes. Examples: C03 quote \"Retrospective human survival comparison p‑value | p=0.01 | N/A\" is not a verbatim line from the report table; C04 quote \"Blocking type I interferon signaling with anti‑IFNAR1 eliminated the observed sensitization benefit.\" is not verbatim; C04/C02 quote \"Interferon‑associated antigen processing and presentation pathways increase.\" is not verbatim. This breaks the pass criterion that references/quotes map correctly to report lines.",
        "public_summary.json introduces potentially overstated language not supported verbatim by the report: \"cutting tumour growth\" implies a demonstrated quantitative tumor-growth reduction, whereas the report states more generally that combination therapy improved tumor control in mice (L46) and that vaccine-only/ICI-only had limitations (L36–L38). The direction is plausible, but the phrasing is more specific/strong than the provided report text.",
        "Calibration risk in headline/summary: stating the intervention \"improve[s] checkpoint inhibitor outcomes in mice and humans\" can be read causally for humans, while the human data are retrospective/non-randomized with likely confounding (L49–L52). The body text does add caution, but the headline still risks overclaiming."
      ],
      "summary": "The outputs largely reflect the report’s main narrative (intratumoral mRNA induces type I IFN, broadens antigen presentation, and is associated with better ICI responses; key caveats about retrospective human data are mentioned). However, they fail strict grading because (1) quantitative_findings.json contains invalid line-reference field types, (2) claim_audit.json misuses non-verbatim text as quotes tied to line refs, and (3) the public-facing wording includes at least one over-specific claim\""
    }
  }
}
